… if a prodrug of acamprosate could inhibit L-DOPA induced dyskinesias (LID).  Functional interactions between the … acamprosate effectively and safely reduced levodopa induced dyskinesias (LID) in animal pre-clinical model of this … cause unwanted side effects. … Symptoms & Side Effects … Dyskinesia … Therapeutic Development … California … United …

…   Dyskinesia is involuntary, irregular movement that can occur … or bothersome. Others actually prefer the extra movement of dyskinesia to being rigid or otherwise unable to move because of PD. (Dyskinesia is typically present when other Parkinson's …

… of L-dopa-induced abnormal involuntary movements (AIMs), or dyskinesias, stemmed from preclinical studies showing that … optimal therapeutic benefit for treatment of L-dopa-induced dyskinesias in PD, with a minimum of side effects. Project … and it leads to disabling complications, including AIMs or dyskinesias that can be as debilitating as PD itself. …

… progresses, debilitating involuntary movements, so-called dyskinesias. The serotonin neurons are known to be able to … produces a near-complete suppression of levodopa-induced dyskinesia in pre-clinical Parkinson models. The serotonin … these compounds to prevent development of levodopa-induced dyskinesia as well as to suppress already established …

… scale for measuring patient response to therapies to treat dyskinesia, the debilitating, uncontrollable movements that … University Medical Center, demonstrated that the Unified Dyskinesia Rating Scale (UDysRS) most sensitively tracks … effect. Establishing UDysRS as a validated tool for use in dyskinesia clinical trials could have important implications …

… Such effects include, abnormal involuntary movements (dyskinesia) and fluctuations in motor function. The … both of which have been implicated in the genesis of dyskinesia. In this project, the levels of activation of … response categories based on the absence or presence of dyskinesia. Drugs that antagonize different types of …